Literature DB >> 25386056

MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.

Nadia Panera1, Daniela Gnani1, Annalisa Crudele1, Sara Ceccarelli1, Valerio Nobili1, Anna Alisi1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a multi-faceted condition including simple steatosis alone or associated with inflammation and ballooning (non-alcoholic steatohepatitis) and eventually fibrosis. The NAFLD incidence has increased over the last twenty years becoming the most frequent chronic liver disease in industrialized countries. Obesity, visceral adiposity, insulin resistance, and many other disorders that characterize metabolic syndrome are the major predisposing risk factors for NAFLD. Furthermore, different factors, including genetic background, epigenetic mechanisms and environmental factors, such as diet and physical exercise, contribute to NAFLD development and progression. Several lines of evidence demonstrate that specific microRNAs expression profiles are strongly associated with several pathological conditions including NAFLD. In NAFLD, microRNA deregulation in response to intrinsic genetic or epigenetic factors or environmental factors contributes to metabolic dysfunction. In this review we focused on microRNAs role both as controlled and controllers molecules in NAFLD development and/or their eventual value as non-invasive biomarkers of disease.

Entities:  

Keywords:  Fibrosis; Liver steatosis; MicroRNAs; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2014        PMID: 25386056      PMCID: PMC4223241          DOI: 10.3748/wjg.v20.i41.15079

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  77 in total

1.  A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.

Authors:  G Hutvágner; J McLachlan; A E Pasquinelli; E Bálint; T Tuschl; P D Zamore
Journal:  Science       Date:  2001-07-12       Impact factor: 47.728

2.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

Review 3.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

Review 4.  Transcription and processing of human microRNA precursors.

Authors:  Bryan R Cullen
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

5.  Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.

Authors:  Sunmi Seok; Dong-Hyun Kim; Sung-E Choi; Ting Fu; Eunkyung Yu; Kwan-Woo Lee; Yup Kang; Xiaoling Li; Byron Kemper; Jongsook Kim Kemper
Journal:  Aging Cell       Date:  2013-08-11       Impact factor: 9.304

Review 6.  Post-transcriptional stimulation of gene expression by microRNAs.

Authors:  Sooncheol Lee; Shobha Vasudevan
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice.

Authors:  Igor P Pogribny; Athena Starlard-Davenport; Volodymyr P Tryndyak; Tao Han; Sharon A Ross; Ivan Rusyn; Frederick A Beland
Journal:  Lab Invest       Date:  2010-06-14       Impact factor: 5.662

8.  Nonalcoholic fatty liver disease as a comorbidity of childhood obesity.

Authors:  Nicole J Barshop; Cameron S Francis; Jeffrey B Schwimmer; Joel E Lavine
Journal:  Ped Health       Date:  2009-06-01

Review 9.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 10.  Small silencing RNAs: an expanding universe.

Authors:  Megha Ghildiyal; Phillip D Zamore
Journal:  Nat Rev Genet       Date:  2009-02       Impact factor: 53.242

View more
  20 in total

Review 1.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 2.  NAFLD: Mechanisms, Treatments, and Biomarkers.

Authors:  Fatiha Nassir
Journal:  Biomolecules       Date:  2022-06-13

Review 3.  Glycosyltransferases and non-alcoholic fatty liver disease.

Authors:  Yu-Tao Zhan; Hai-Ying Su; Wei An
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 4.  MicroRNAs in Nonalcoholic Fatty Liver Disease.

Authors:  György Baffy
Journal:  J Clin Med       Date:  2015-12-04       Impact factor: 4.241

Review 5.  Potential epigenetic mechanism in non-alcoholic Fatty liver disease.

Authors:  Chao Sun; Jian-Gao Fan; Liang Qiao
Journal:  Int J Mol Sci       Date:  2015-03-05       Impact factor: 5.923

6.  Hepatic Lipid Accumulation and Nrf2 Expression following Perinatal and Peripubertal Exposure to Bisphenol A in a Mouse Model of Nonalcoholic Liver Disease.

Authors:  Prajakta C Shimpi; Vijay R More; Maneesha Paranjpe; Ajay C Donepudi; Jaclyn M Goodrich; Dana C Dolinoy; Beverly Rubin; Angela L Slitt
Journal:  Environ Health Perspect       Date:  2017-08-04       Impact factor: 9.031

7.  miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.

Authors:  Junjie Xiao; Yihua Bei; Jingqi Liu; Jasmina Dimitrova-Shumkovska; Dapeng Kuang; Qiulian Zhou; Jin Li; Yanning Yang; Yang Xiang; Fei Wang; Changqing Yang; Wenzhuo Yang
Journal:  J Cell Mol Med       Date:  2015-12-09       Impact factor: 5.310

8.  miR-149 controls non-alcoholic fatty liver by targeting FGF-21.

Authors:  Junjie Xiao; Dongchao Lv; Yingying Zhao; Xiaoyu Chen; Meiyi Song; Jingqi Liu; Yihua Bei; Fei Wang; Wenzhuo Yang; Changqing Yang
Journal:  J Cell Mol Med       Date:  2016-04-06       Impact factor: 5.310

9.  miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.

Authors:  Teresa Auguet; Gemma Aragonès; Alba Berlanga; Esther Guiu-Jurado; Andreu Martí; Salomé Martínez; Fàtima Sabench; Mercé Hernández; Carmen Aguilar; Joan Josep Sirvent; Daniel Del Castillo; Cristóbal Richart
Journal:  Int J Mol Sci       Date:  2016-09-24       Impact factor: 5.923

10.  Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity.

Authors:  Mona A Hegazy; Ibrahim Abd ALgwad; Soheir Abuel Fadl; Mohamed Sayed Hassan; Laila Ahmed Rashed; Maha A Hussein
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-19       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.